Gilead sciences inc

Gilead Sciences, Inc.
Company type	Public
Traded as	NASDAQ: GILD; NASDAQ Biotechnology Component; NASDAQ-100 Component; S&P 100 Component; S&P 500 Component;
Industry	Pharmaceutics; Biotechnology
Founded	June 22, 1987; 37 years ago
Headquarters	Foster City, California, United States
Area served	Worldwide
Key people	Daniel O'Day; (CEO and Chairman); Andrew Dickinson; (CFO); Tomáš Cihlář; (Vice president, and; Senior Director, Biology);
Products	AmBisome; Atripla; Biktarvy; Complera; Cayston; Descovy; Emtriva; Epclusa; Genvoya; Harvoni; Hepsera; Letairis; Lexiscan; Macugen; Odefsey; Ranexa; Sovaldi; Stribild; Tamiflu; Truvada; Tybost; Veklury; Vemlidy; Viread; Vosevi; Yescarta; Zydelig;
Revenue	US$22.45 billion (2019)
Operating income	US$4.29 billion (2019)
Net income	US$5.39 billion (2019)
Total assets	US$61.63 billion (2019)
Total equity	US$22.65 billion (2019)
Number of employees	11,800 (2019)

Gilead Sciences is a pharmaceutical company based in Forster City, California established in the year 1987.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.